USD 1.05
(-1.87%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 558.09 Thousand USD | -61.62% |
2022 | 1.45 Million USD | 32.96% |
2021 | 1.09 Million USD | 1110.44% |
2020 | 90.36 Thousand USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 652 Thousand USD | 16.83% |
2024 Q2 | 796.61 Thousand USD | 22.18% |
2023 FY | 558.09 Thousand USD | -61.62% |
2023 Q2 | 2.62 Million USD | 20.19% |
2023 Q1 | 2.18 Million USD | 50.38% |
2023 Q4 | 558.09 Thousand USD | -38.19% |
2023 Q3 | 902.9 Thousand USD | -65.65% |
2022 Q4 | 1.45 Million USD | 0.0% |
2022 FY | 1.45 Million USD | 32.96% |
2022 Q3 | - USD | 0.0% |
2022 Q1 | 670.49 Thousand USD | 0.0% |
2021 Q1 | - USD | 0.0% |
2021 FY | 1.09 Million USD | 1110.44% |
2020 FY | 90.36 Thousand USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Amgen Inc. | 90.92 Billion USD | 99.999% |
AstraZeneca PLC | 61.95 Billion USD | 99.999% |
Biogen Inc. | 12.04 Billion USD | 99.995% |
Gilead Sciences, Inc. | 39.37 Billion USD | 99.999% |
Scilex Holding Company | 274.24 Million USD | 99.796% |
Scilex Holding Company | 274.24 Million USD | 99.796% |